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Escherichia coli infections are frequent in ICU patients. The increased resistance
to fluoroquinolones and amoxicillin/clavulanate of this pathogen mandates the
prescription of broad-spectrum antibiotics such as piperacillin/tazobactam (PIP-
TAZ) or third generation cephalosporins (3GC).
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